To date, only one other study has investigated the predictive value of metabolic and volumetric variables concerning the use of pretreatment 18F-FDG PET/CT in advanced lung adenocarcinoma patients stratified by EGFR mutation status using the RECIST 1.1 criteria [30]. This evidence concerns the gene EGFR and lung adenocarcinoma.